Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Goodyear Tire & Rubber Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Goodyear Tire & Rubber Co trades at $6.92 (market cap $1.96B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 20.4× Goodyear Tire & Rubber Co's market cap, and Goodyear Tire & Rubber Co is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GT | |
|---|---|---|
Market Cap | $39.89B | $1.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $11.54 |
52-Week Low | $278.09 | $5.58 |
Enterprise Value | $38.15B | $9.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Goodyear Tire & Rubber (GT) trades at $6.81, up 2.56% with a bullish technical signal despite recent earnings volatility. The stock shows attractive valuation metrics with P/E of 4.69 and P/S of 0.11, but faces profitability challenges with negative net income margin of -11.64% and ROE of -52.56%. Recent developments include the company's move to the S&P SmallCap 600 and NASA lunar tire contract, while analyst consensus targets $8.80 with mixed ratings.
The outlook remains cautious due to persistent operational headwinds and declining revenue trends, though current valuations appear discounted. Investment opportunity exists if Goodyear Forward program benefits materialize, but risks include weak tire demand, margin pressure, and high debt levels. The stock trades near 52-week lows, reflecting market skepticism about near-term turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
